Advaxis Requests Orphan Drug Designation for Treatment of Cervical Cancer … – DailyFinance

Advaxis Requests Orphan Drug Designation for Treatment of Cervical Cancer
DailyFinance
"We are optimistic about our request for Orphan Drug Designation for ADXS-HPV in the indication of invasive cervical cancer," commented Dr. Robert Petit, Chief Scientific Officer of Advaxis. "Data recently presented at the 2013 ASCO Annual Meeting from

View full post on hpv – Google News

Leave a Reply

Your email address will not be published. Required fields are marked *